June 23, 2017 / 11:48 AM / a month ago

BRIEF-Novo Nordisk: EMA committee issues positive opinion for Victoza label update

1 Min Read

June 23 (Reuters) - Novo Nordisk A/S

* The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion on update of the EU label for Victoza

* The update is based on the results from the LEADER trial which investigated the long-term effects of Victoza in people with type 2 diabetes, at high risk of major cardiovascular events

* The CHMP positive opinion for Victoza(®) is now referred to the European Commission, which grants approval in the EU, for final action on the proposed indication

* Novo Nordisk expects to receive the European Commission decision for the Victoza label update in the third quarter of 2017 Source text for Eikon: Further company coverage: (Reporting by Stine Jacobsen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below